Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin G1 is a protein that plays a role in growth regulation and is associated with cell cycle control, particularly at the G2/M phase checkpoint. It can induce cell cycle arrest at this stage in response to DNA damage. Transcriptional activation of CCNG1 can be induced by tumor suppressor p53, suggesting it acts as an intermediate through which p53 mediates its effects on cell cycle arrest and DNA repair pathways. It has also been implicated in spatial coupling between autophagy compartments and mTOR signaling during cellular stress responses. Altered expression or regulation of Cyclin G1 has been linked to cancer development, making it a potential biomarker for cancer prognosis and therapy selection.
Dominant-negative forms of Cyclin G1 have shown anticancer activity by triggering programmed cell death (apoptosis). MicroRNAs such as miR-516b act as tumor suppressors by directly targeting CCNG1 expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin G1 (CCNG1).